tacti-002 and tacti-003: eftilagimod alpha for metastatic head and neck squamous cell carcinoma
Published 2 years ago • 265 plays • Length 2:55Download video MP4
Download video MP3
Similar videos
-
1:56
eftilagimod alpha and pembrolizumab in patients with squamous head and neck carcinoma
-
2:54
final update on aipac: eftilagimod alpha plus paclitaxel in patients with metastatic hr her2- bc
-
2:14
mechanism of action of eftilagimod alpha for the treatment of breast cancer
-
4:59
phase i insight platform trial: eftilagimod alpha with avelumab in advanced solid tumors
-
1:59
potential of immunotherapy in head and neck cancer
-
3:11
aipac: final results of phase iib trial of eftilagimod alpha vs placebo with chemo for hr her2- mbc
-
1:44
immunotherapy: how t cells fight cancer
-
37:39
immunotherapy
-
1:26
moffitt medical minute (ep. 41) - lag3
-
5:00
what is cellular immunotherapy? is it the same as adoptive cell therapy?
-
29:34
immunotherapy
-
2:42
‘different immunotherapies for different patients’
-
2:23
immunotherapy 2.0: smarter use, better results
-
1:06:01
multiscale analysis of in situ tumor biology towards precision medicine
-
8:00
introduction to imaging in immunotherapy
-
26:32
standard and alternative dosing regimens of immunotherapies and combinations in modern oncology
-
2:25
bispectral index™ byte 2: the bis™ index range
-
3:03
what is tasquinimod?
-
3:00
immunotherapy #cancer #immunotherapy